The oversubscribed funding round was led by new international biotech investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon Capital Partners, Novartis Venture Fund and Vesalius Biocapital also participated in the round.

The proceeds will fund the expansion of the company’s broad Phase 2b development of Visugromab into randomized Phase 2b studies in select checkpoint naïve frontline and second-line treatment settings. Visugromab is a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor 15, which acts as a key regulator of immune resistance to cancer therapies. Visugromab has already demonstrated outstanding anti-tumor activity in combination with checkpoint inhibitor treatment.

Hogan Lovells has regularly been providing legal counsel to CatalYm since its Series-B extension round in 2021, showcasing a strong ongoing partnership.